8-K/A: SeaStar Medical to Restate Financials, Announces Business Update Call

SeaStar Medical will restate financial statements for 2022 and interim 2023 periods due to accounting treatment of warrants and a prepaid forward purchase arrangement, but expects no material impact on cash or operations.

Summary

• SeaStar Medical will restate its financial statements for the fiscal year ended December 31, 2022, and the interim periods ended March 31, 2023, June 30, 2023, and September 30, 2023.
• The restatement is due to the accounting treatment of certain outstanding warrants and a prepaid forward purchase arrangement that was terminated in June 2023.
• The company expects to file Form 12b-25 with the SEC, which provides a 15-day grace period for filing the Annual Report on Form 10-K.
• The restatement is not expected to have a material impact on the company's business operations or cash position, as it relates to non-cash accounting items.
• SeaStar Medical pursued a SPAC route to become a public company in late 2022 due to challenging market conditions, which involved complex financial instruments.
• The company's pivotal adult acute kidney injury (AKI) study has enrolled 23 subjects, with two additional subjects since the last update two weeks ago.
• The first critically ill child with AKI and sepsis or septic condition is expected to be treated with the Quelimmune pediatric therapeutic device in the second quarter of 2024.
• SeaStar Medical will hold a business update conference call on April 17, 2024, to provide a more detailed update on its progress and outlook.

Sentiment

Score: 4

Explanation: The need for a financial restatement and the delay in filing the annual report are negative signals. However, the company is making progress with its clinical trials and commercial launch, which provides some positive outlook. The overall sentiment is cautiously negative.

Positives

• The restatement is not expected to have a material impact on the company's cash position or operations.
• The company is making progress with its pivotal adult AKI study, with 23 subjects enrolled.
• The commercial launch of the Quelimmune pediatric device is progressing, with the first patient treatment expected in Q2 2024.
• The FDA granted HDE approval for the Quelimmune pediatric device in February 2024.
• The company is actively engaging with key opinion leaders and sharing valuable insights into AKI and sepsis.

Negatives

• The company needs to restate its financial statements due to errors in accounting treatment of complex financial instruments.
• The restatement requires additional audit procedures and a delay in filing the Annual Report on Form 10-K.
• The company had to use a SPAC to go public due to challenging market conditions in 2022.

Risks

• The company may not be able to obtain regulatory approval for its SCD product candidates.
• SeaStar Medical may not be able to raise sufficient capital to fund its operations, including clinical trials.
• The company and its collaborators may experience delays in developing and commercializing its products.
• SeaStar Medical may never achieve or sustain profitability.
• The company may not be able to access funding under existing agreements.
• Third-party suppliers and manufacturers may not meet their obligations.
• The company faces the risk of product liability or regulatory lawsuits.
• SeaStar Medical may be unable to secure or protect its intellectual property.

Future Outlook

SeaStar Medical plans to provide a more detailed update on its progress and outlook during its business update conference call on April 17, 2024. The company expects to treat the first pediatric patient with Quelimmune in the second quarter of 2024.

Management Comments

• The restatement is not expected to have a material impact on our business operations or our cash position, but rather is related to the reporting of non-cash accounting items, said Eric Schlorff, Chief Executive Officer of SeaStar Medical.
• We pursued a Special Purpose Acquisition Company (SPAC) as our route to become a public company in late 2022 due to the challenging market conditions at that time.
• Unfortunately, we determined that certain complex financial instruments required accounting treatment that differed from our previous judgment, which led to the need for a restatement.
• Importantly, we continue to make progress with our pivotal adult acute kidney injury (AKI) study with 23 subjects enrolled, including two additional subjects since our last update two weeks ago.
• With our commercial launch of the Quelimmune pediatric therapeutic device, the first critically ill child with AKI and sepsis or septic condition is expected to be treated at a well-recognized childrens hospital in the second quarter of 2024.

Industry Context

The need for restatement due to complex financial instruments is not uncommon among companies that went public via SPACs, especially during the challenging market conditions of 2022. The company's focus on addressing hyperinflammation and AKI aligns with the growing need for innovative therapies in critical care.

Comparison to Industry Standards

• The use of SPACs for going public was a common trend in 2022, and many companies faced similar accounting challenges with complex financial instruments.
• The enrollment of 23 subjects in the adult AKI trial is a positive step, but the total target of 200 is still a significant undertaking.
• The estimated 4,000 annual eligible pediatric patients for Quelimmune represents a significant market opportunity, but the actual adoption rate will depend on clinical outcomes and market penetration.
• Companies like Baxter and Fresenius Medical Care are major players in the kidney replacement therapy market, and SeaStar Medical will need to demonstrate a clear clinical and economic advantage to gain market share.

Stakeholder Impact

• Shareholders may be concerned about the financial restatement and the delay in filing the annual report.
• Employees may be affected by the uncertainty surrounding the financial restatement.
• Customers and patients may be interested in the progress of the clinical trials and the commercial launch of Quelimmune.
• Suppliers and creditors may be monitoring the company's financial health.

Next Steps

• SeaStar Medical will file Form 12b-25 with the SEC.
• The company will restate its financial statements for the specified periods.
• SeaStar Medical will hold a business update conference call on April 17, 2024.
• The company expects to treat the first pediatric patient with Quelimmune in the second quarter of 2024.

Key Dates

Keywords

SeaStar Medical, Financial Restatement, Quelimmune, Acute Kidney Injury, AKI, SCD, Hyperinflammation, Medical Device, Clinical Trial, Pediatric, Warrants, SPAC